Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18106- 138-immunoglobulin G in whole blood

Infection and Immunity

Volumn 65, Issue 6, 1997, Pages 2160-2167

  Ogata, Masanori ^a,b,e   Fletcher, Mark F ^a,f   Kloczewiak, Marek ^c   Loiselle, Paul M ^a   Zanzot, Emily M ^a   Vermeulen, Mary W ^d   Warren, H Shaw ^a,e,g  

^a Infectious Disease Unit   (United States)

^b Department of Anesthesiology ^*  (United States)

^c CURIS INC   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Hebrew Senior Life   (United States)

^f Pasteur Merieux Connaught   (France)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ANTIGEN BINDING; ARTICLE; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INDUCTION;

EID: 0030976391     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.6.2160-2167.1997     Document Type: Article

References (50)

1. Abukhabar, K. S., J. A. Armstrong, and M. Ho. 1992. Type-1 interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J. Leukocyte Biol. 52:165-172.
2. Ammons, W. S., F. R. Kohn, and A. H. C. Kung. 1994. Protective effects of an N-terminal fragment of bactericidal/permeability increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. J. Infect. Ois. 170:1473-1482.
3. Arditi, M., J. Zhou, S. H. Huang, P. M. Luckett, M. N. Marra, and K. S. Kim. 1994. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. Infect. Immun. 62:3930-3936.
4. Cannon, J. G., J. W. M. Van der Meer, D. Kwiatkowski, S. Endres, G. Lonnemann, J. F. Burke, and C. A. Dinarello. 1988. Interleukin-1b in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res. 7:457-467.
5. Carlsson, J., H. Drevin, and R. Axen. 1978. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterofunctional reagent. Biochem. J. 173:723-737.
6. Cavaillon, J.-M., C. Fitting, N. Haeffner-Cavaillon, S. J. Kirsch, and H. S. Warren. 1990. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect. Immun. 58:2325-2382.
7. Drabick, J., A. Bhattacharjee, W. Williams, G. Siber, and A. S. Cross. 1992. Covalent polymyxin B-starch and polymyxin B-immunoglobulin G conjugates as novel anti-endotoxin agents. Clin. Res. 40:287A.
8. 2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J. Biol. Chem. 254:11000-11009.
9. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99-105.
10. Fletcher, M. A., M. Kloczewiak, P. M. LoIselle, S. F. Amato, K. M. Black, and H. S. Warren. 1996. TALF peptide-immunoglobulin conjugates that bind lipopolysaccharide. J. Endotoxin Res. 3:49-55.
11. 106-138-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. J. Infect. Dis. 175:621-632.
12. 11a.Fletcher, M. A., et al. Unpublished data.
13. Gallay, P., D. Heumann, D. Le Roy, C. Barras, and M. P. Glauser. 1993. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc. Natl. Acad. Sci. USA 90:9935-9938.
14. Helinski, E. H., K. L. Bielat, G. M. Ovak, and J. L. Pauly. 1988. Long-term cultivation of functional human macrophages in Teflon dishes with serum-free media. J. Leukocyte Biol. 44:111-121.
15. Hirata, M., V. Shimomura, M. Yoshida, J. G. Morgan, I. Palings, D. Wilson, M. H. Yen, S. C. Wright, and J. W. Larrick. 1994. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect. Immun. 62:1421-1426.
16. Hoess, A., S. Watson, G. R. Siber, and R. Liddington. 1993. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab. Limulus anti-LPS factor, at 1.5 Å resolution. EMBO J. 12:3351-3350.
17. Hudson, D. 1993. Methodological implications of simultaneous solid-phase peptide synthesis. I. Comparison of different coupling procedures. J. Org. Chem. 53:617-662.
18. Kloczewiak, M., K. M. Black, P. Loiselle, J.-M. Cavaillon, N. Wainwright, and H. S. Warren. 1994. Synthetic peptides that mimic the binding site of horseshoe crab anti-lipopolysaccharide factor. J. Infect. Dis. 170:1490-1497.
19. Kohn, F. R., W. S. Ammons, A. Horwitz, L. Grinna, G. Theofan, J. Weickmann, and A. H. C. Kung. 1993. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability increasing protein in experimental endotoxemia. J. Infect. Dis. 168:1307-1310.
20. Larrick, J. W., M. Hirata, R. F. Balint, J. Lee, J. Zhong, and S. C. Wright. 1945. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect, Immun. 63:1291-1297.
21. Larrick, J. W., M. Hirata, Y. Shimomoura, M. Yoshida, H. Zheng, J. Zhong, and S. C. Wright. 1993. Antimicrobial activity of rabbit CAP18-derived peptides. Antimicrob. Agents Chemother. 37:2534-2539.
22. Larrick, J. W., M. Hirata, H. Zheng, J. Zhong, D. Bolin, J.-M. Cavaillon, H. S. Warren, and S. C. Wright. 1994. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J. Immunol. 152:231-240.
23. 23). J. Biol. Chem. 269:1865-1872.
24. Munford, R. S., C. L. Hall, J. M. Lipton, and J. M. Dietschy. 1982. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J. Clin. Invest. 70:877-888.
25. Nerad, J. L., J. K. Griffiths, J. W. M. Van der Meer, S. Endres, D. D. Poutsiaka, G. T. Keusch, M. Bennish, M. A. Salam, C. A. Dinarello, and J. G. Cannon. 1992. Interleukin-1b (IL-1b), IL-1 receptor antagonist, and TNF-α production in whole blood. J. Leukocyte Biol. 52:687-092.
26. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60 kDa bactericidal/permeability-increasing protein. J. Biol. Chem. 262:14891-14894.
27. Piers, K. L., M. H. Brown, and R. E. W. Hancock. 1994. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. Antimicrob. Agents Chemother. 38:2311-2316.
28. Prins, J. M., E. J. Kuijper, M. L. C. M. Mevissen, P. Speelman, and S. J. H. van Deventer. 1995. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun, 63:2236-2242.
29. Riches, P., R. Gooding, B. C. Millar, and A. W. Rowbottom. 1992. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations. J. Immunol. Methods 153:125-131.
30. Romeo, D., A. Girard, and L. Rothfield. 1970. Reconstitution of a functional membrane enzyme system in a monomolecular film. I. Formation of mixed monolayer of lipopolysaccharide and phospholipid. J. Mol. Biol. 53:475-490.
31. Rudbach, J. A., F. I. Akiya, R. J. Elin, H. D. Hochstein, M. K. Luoma, E. C. B. Milner, K. C. Milner, and K. R. Thomas. 1976. Preparation and properties of a national reference endotoxin. J. Clin. Microbiol. 3:21-25.
32. Schumann, R. R., S. R. Leung, G. W. Flaggs, P. W. Gray, S. D. Wright, J. C. Mathison, P. S. Tobias, and R. J. Ulevitch. 1990. Structure and function of lipopolysaccharide-binding protein. Science 249:1429-1431.
33. Siber, G. R., S. A. Kania, and H. S. Warren. 1985. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 152:954-964.
34. Skarnes, R. C. 1995. The inactivation of endotoxin after interaction with certain proteins of normal serum. Ann. N. Y. Acad. Sci. 644-662.
35. Thavasu, P. W., S. Longhurst, S. P. Joel, M. L. Slevin, and F. R. Balkwill, 1992. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Methods 153:115-124.
36. Tobias, P. S., J. Mathison, D. Mintz, J. Lee, V. Kravchenko, K. Kato, J. Pugin, and R. J. Ulevitch. 1992. Participation of lipopolysaccharide-binding protein in lipopolysaccharide-dependenl macrophage activation. Am. J. Cell Mol. Biol. 7:239-245.
37. Tobias, P. S., J. Soldau, and R. J. Ulevitch. 1986. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J. Exp, Med. 164:777-793.
38. Tossi, A., M. Scocchi, B. Skerlavaj, and R. Gennaro. 1994. Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett. 339:108-112.
39. Ulevitch, R. J. 1993. Recognition of bacterial endotoxins by receptor-dependent mechanisms. Adv. Immunol. 53:267-289.
40. Ulevitch, R. J., and A. R. Johnston. 1978. The modification of biophysical and endotoxin properties of bacterial lipopolysaccharides by serum. J. Clin. Invest. 62:1313-1324.
41. Ulevitch, R. J., A. R. Johnston, and D. B. Weinstein. 1979. New function of high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J. Clin. Invest. 64:1516-1524.
42. Vandermeer, T. J., M. J. Menconi, J. Zhuang, H. Wang, R. Murtaugh, C. Bouza, P. Stevens, and M. P. Fink. 1995. Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs. Surgery 117:656-662.
43. von der Mohlen, M. A. M., A. N. Kimmings, N. I. Wedel, M. L. C. M. Mevissen, J. Jansen, N. Friedmann, T. J. Lorenz, B. J. Nelson, M. L. White, R. Bauer, C. E. Hack, A. J. M. Eerenberg, and S. J. H. van Deventer. 1995. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J. Infect. Dis. 172:144-151.
44. Warren, H. S., S. F. Amato, C. Fitting, K. M. Black, P. M. Loiselle, M. S. Pasternack, and J.-M. Cavaillon. 1993. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177:89-97.
45. Warren, H. S., C. V. Knights, and G. R. Siber. 1986. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J. Infect. Dis. 154:784-791.
46. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 90:1122-1130.
47. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides. Methods Carbohydr. Chem. 5:83.
48. Wilson, B. M. G., A. Severn, N. T. Rapson, J. Chana, and P. Hopkins. 1991. A convenient human whole blood culture system for studying the regulation of tumour necrosis factor release by bacterial lipopolysaccharide. J. Immunol. Methods 139:233-240.
49. Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.
50. Wurfel, M. M., S. T. Kunitake, H. Lichenstein, J. P. Kane, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180:1025-1035.